{
    "medicine_id": "c3e458611a605aceb9a640c2efecf7279aded09a",
    "platform_id": "DB15466",
    "metadata": {
        "name": "Apadaz Tablet",
        "composition": "Tallimustine",
        "clinical_particulars": {
            "therapeutic_indications": "Tallimustine was being investigated for its use in treating tumors A182036 A182039 Derivatives of tallimustine with similar DNA binding ability and reduced myelotoxicity are being investigated for their antitumor activity A182039",
            "contraindications": {
                "disease": "Tallimustine is associated with myelotoxicity severe enough to stop its development A182036 A182039",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "NA",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tallimustine"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tallimustine"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tallimustine"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Tallimustine"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}